Inicio
Autor Mendizabal, Manuel
|
|
Documentos disponibles escritos por este autor (2)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaHepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis / Juan Ignacio Marín Zuluaga ; Piñero, Federico ; Anders, Margarita ; Bermudez, Carla ; Arufe, Diego ; Varón, Adriana ; Palazzo, Ana ; Rodriguez, Jorge ; Beltrán, Oscar ; Simia, Daniela ; Gomes da Fonseca, Leonardo ; Ridruejo, Ezequiel ; Tamagnone, Norberto ; Cheinquer, Hugo ; Bejarano, Diana ; Orozco, Federico ; Pages, Josefina ; Poniachik, Jaime ; Marciano, Sebastián ; Reggiardo, Virginia ; Silva, Marcelo ; Mendizabal, Manuel
Título : Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, Autor ; Piñero, Federico, Autor ; Anders, Margarita, Autor ; Bermudez, Carla, Autor ; Arufe, Diego, Autor ; Varón, Adriana, Autor ; Palazzo, Ana, Autor ; Rodriguez, Jorge, Autor ; Beltrán, Oscar, Autor ; Simia, Daniela, Autor ; Gomes da Fonseca, Leonardo, Autor ; Ridruejo, Ezequiel, Autor ; Tamagnone, Norberto, Autor ; Cheinquer, Hugo, Autor ; Bejarano, Diana, Autor ; Orozco, Federico, Autor ; Pages, Josefina, Autor ; Poniachik, Jaime, Autor ; Marciano, Sebastián, Autor ; Reggiardo, Virginia, Autor ; Silva, Marcelo, Autor ; Mendizabal, Manuel, Autor Fecha de publicación : 2025 Títulos uniformes : Liver International Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave : cirrhosis; liver cancer; outcomes; prognosis; real world; recompensation. Resumen : Background and aims: The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first-line systemic therapies remain unclear. We compared survival from the initiation of first-line systemic treatments for advanced HCC among patients with compensated, decompensated, and recompensated cirrhosis. Methods: A Latin American multicenter, prospective cohort study was conducted from 2018 to 2024, involving patients with HCC and Child-Pugh class A or B who received systemic therapy. At the time of first-line therapy, patients with cirrhosis were categorised as compensated (never decompensated), decompensated, or recompensated. Cox proportional hazards models were estimated. Results: Among 306 patients receiving first-line systemic therapy (sorafenib: 60.5%, atezolizumab + bevacizumab: 29.7%, lenvatinib: 9.1%), 240 had cirrhosis, with 30.4% having a history of hepatic decompensation. Of these, 57.5% (95% CI 45.4%-69.0%) achieved hepatic recompensation over a median period of 12 months. At the time of first-line therapy, 69.6% were compensated, 17.5% recompensated, and 12.9% decompensated. Metabolic-associated steatotic liver disease (MASLD) was the most common underlying aetiology in the recompensated group. Median survival was significantly shorter in the decompensated group (8.6 months) compared to the compensated group (17.2 months) [aHR 1.91 (95% CI 1.04-3.5); p = 0.03], without a significant difference between the recompensated and compensated groups [aHR 1.28 (95% CI 0.79-2.1); p = 0.31]. Tumour progression was the primary reason for treatment discontinuation, and similar access to second-line therapies was observed between the compensated and recompensated groups. Conclusion: Patients with cirrhosis and advanced HCC who achieved hepatic recompensation might benefit from systemic therapies after a cautious observation period. Mención de responsabilidad : Federico Piñero, Margarita Anders, Carla Bermudez, Diego Arufe, Adriana Varón, Ana Palazzo, Jorge Rodriguez, Oscar Beltrán, Daniela Simian, Leonardo Gomes da Fonseca, Ezequiel Ridruejo, Norberto Tamagnone, Hugo Cheinquer, Diana Bejarano, Juan Ignacio Marín, Federico Orozco, Josefina Pages, Jaime Poniachik, Sebastián Marciano, Virginia Reggiardo, Marcelo Silva, Manuel Mendizabal Referencia : Liver Int . 2025 May;45(5):e70092 DOI (Digital Object Identifier) : 10.1111/liv.70092 PMID : 40208044 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40208044/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis [documento electrónico] / Juan Ignacio Marín Zuluaga, Autor ; Piñero, Federico, Autor ; Anders, Margarita, Autor ; Bermudez, Carla, Autor ; Arufe, Diego, Autor ; Varón, Adriana, Autor ; Palazzo, Ana, Autor ; Rodriguez, Jorge, Autor ; Beltrán, Oscar, Autor ; Simia, Daniela, Autor ; Gomes da Fonseca, Leonardo, Autor ; Ridruejo, Ezequiel, Autor ; Tamagnone, Norberto, Autor ; Cheinquer, Hugo, Autor ; Bejarano, Diana, Autor ; Orozco, Federico, Autor ; Pages, Josefina, Autor ; Poniachik, Jaime, Autor ; Marciano, Sebastián, Autor ; Reggiardo, Virginia, Autor ; Silva, Marcelo, Autor ; Mendizabal, Manuel, Autor . - 2025.
Obra : Liver International
Idioma : Inglés (eng) Idioma original : Inglés (eng)
Palabras clave : cirrhosis; liver cancer; outcomes; prognosis; real world; recompensation. Resumen : Background and aims: The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first-line systemic therapies remain unclear. We compared survival from the initiation of first-line systemic treatments for advanced HCC among patients with compensated, decompensated, and recompensated cirrhosis. Methods: A Latin American multicenter, prospective cohort study was conducted from 2018 to 2024, involving patients with HCC and Child-Pugh class A or B who received systemic therapy. At the time of first-line therapy, patients with cirrhosis were categorised as compensated (never decompensated), decompensated, or recompensated. Cox proportional hazards models were estimated. Results: Among 306 patients receiving first-line systemic therapy (sorafenib: 60.5%, atezolizumab + bevacizumab: 29.7%, lenvatinib: 9.1%), 240 had cirrhosis, with 30.4% having a history of hepatic decompensation. Of these, 57.5% (95% CI 45.4%-69.0%) achieved hepatic recompensation over a median period of 12 months. At the time of first-line therapy, 69.6% were compensated, 17.5% recompensated, and 12.9% decompensated. Metabolic-associated steatotic liver disease (MASLD) was the most common underlying aetiology in the recompensated group. Median survival was significantly shorter in the decompensated group (8.6 months) compared to the compensated group (17.2 months) [aHR 1.91 (95% CI 1.04-3.5); p = 0.03], without a significant difference between the recompensated and compensated groups [aHR 1.28 (95% CI 0.79-2.1); p = 0.31]. Tumour progression was the primary reason for treatment discontinuation, and similar access to second-line therapies was observed between the compensated and recompensated groups. Conclusion: Patients with cirrhosis and advanced HCC who achieved hepatic recompensation might benefit from systemic therapies after a cautious observation period. Mención de responsabilidad : Federico Piñero, Margarita Anders, Carla Bermudez, Diego Arufe, Adriana Varón, Ana Palazzo, Jorge Rodriguez, Oscar Beltrán, Daniela Simian, Leonardo Gomes da Fonseca, Ezequiel Ridruejo, Norberto Tamagnone, Hugo Cheinquer, Diana Bejarano, Juan Ignacio Marín, Federico Orozco, Josefina Pages, Jaime Poniachik, Sebastián Marciano, Virginia Reggiardo, Marcelo Silva, Manuel Mendizabal Referencia : Liver Int . 2025 May;45(5):e70092 DOI (Digital Object Identifier) : 10.1111/liv.70092 PMID : 40208044 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40208044/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002365 AC-2025-048 Archivo digital Producción Científica Artículos científicos Disponible
Título : Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Autor ; Codes, Liana, Autor ; Zapata, Rodrigo, Autor ; Mendizabal, Manuel, Autor ; Fleck Junior, Alfeu de Medeiros, Autor ; de Lucca Schiavon, Leonardo, Autor ; Sá Malbouisson, Luiz Marcelo, Autor ; Andraus, Wellington, Autor ; Gadano, Adrian, Autor ; Padilla Machaca, P Martin, Autor ; Bello Stucchi, Raquel Silveira, Autor ; Castro Narro, Graciela Elia, Autor ; Pages, Josefina, Autor ; Benedita Terrabuio, Debora Raquel, Autor ; Urzúa, Álvaro, Autor ; Guimarães Pesso, Mário, Autor ; Mainardi, Victoria, Autor ; Rodolpho, Pedro, Autor ; Imventarza, Oscar, Autor ; Gerona, Solange, Autor ; Wolff, Rodrigo, Autor ; Abdala, Edson, Autor ; Tenorio, Laura, Autor ; Cerda Reyes, Eira, Autor ; Cairo, Fernando, Autor ; Uribe, Mario, Autor ; Lisboa Bittencourt, Paulo, Autor Fecha de publicación : 2025 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Immunosuppression; Latin America; Liver transplantation; Postoperative care Resumen : Liver transplantation (LT) is a well-established therapy for patients with decompensated cirrhosis and early-stage hepatocellular carcinoma. Liver transplantation activity varies sharply across Latin American (LATAM) countries due to differences in resources, expertise, and funding and local attitudes toward organ donation and transplantation. This current guidance of postoperative care after LT is the first position paper of the Latin American Association for the Study of the Liver (ALEH) Special Interest Group (SIG), drawing evidence-based recommendations regarding immediate and long-term postoperative care of LT recipients, taking into consideration their applicability in Latin America. © 2025 Fundación Clínica Médica Sur, A.C. Mención de responsabilidad : Codes, Liana; Zapata, Rodrigo; Mendizabal, Manuel; Junior, Alfeu de Medeiros Fleck; Restrepo, Juan Carlos; Schiavon, Leonardo de Lucca; Malbouisson, Luiz Marcelo Sá; Andraus, Wellington; Gadano, Adrian; Padilla-Machaca, P. Martin; Villamil, Alejandra; Stucchi, Raquel Silveira Bello; Castro-Narro, Graciela Elia; Pages, Josefina; Terrabuio, Debora Raquel Benedita; Urzúa, Alvaro; Pessoa, Mário Guimarães; Mainardi, Victoria; Pedro, Rodolpho; Imventarza, Oscar; Gerona, Solange; Wolff, Rodrigo; Abdala, Edson; Tenorio, Laura; Cerda-Reyes, Eira; Cairo, Fernando; Uribe, Mario; Bittencourt, Paulo Lisboa; Chong, Ricardo; Figueroa, Norma Marlene Perez; González, John Byron Abad; Murillo, Pablo Coste. Referencia : Ann Hepatol . 2025 Mar 7;30(2):101899. doi: 10.1016/j.aohep.2025.101899. DOI (Digital Object Identifier) : 10.1016/j.aohep.2025.101899 PMID : 40057036 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40057036/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation [documento electrónico] / Juan Carlos Restrepo Gutiérrez, Autor ; Codes, Liana, Autor ; Zapata, Rodrigo, Autor ; Mendizabal, Manuel, Autor ; Fleck Junior, Alfeu de Medeiros, Autor ; de Lucca Schiavon, Leonardo, Autor ; Sá Malbouisson, Luiz Marcelo, Autor ; Andraus, Wellington, Autor ; Gadano, Adrian, Autor ; Padilla Machaca, P Martin, Autor ; Bello Stucchi, Raquel Silveira, Autor ; Castro Narro, Graciela Elia, Autor ; Pages, Josefina, Autor ; Benedita Terrabuio, Debora Raquel, Autor ; Urzúa, Álvaro, Autor ; Guimarães Pesso, Mário, Autor ; Mainardi, Victoria, Autor ; Rodolpho, Pedro, Autor ; Imventarza, Oscar, Autor ; Gerona, Solange, Autor ; Wolff, Rodrigo, Autor ; Abdala, Edson, Autor ; Tenorio, Laura, Autor ; Cerda Reyes, Eira, Autor ; Cairo, Fernando, Autor ; Uribe, Mario, Autor ; Lisboa Bittencourt, Paulo, Autor . - 2025.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Immunosuppression; Latin America; Liver transplantation; Postoperative care Resumen : Liver transplantation (LT) is a well-established therapy for patients with decompensated cirrhosis and early-stage hepatocellular carcinoma. Liver transplantation activity varies sharply across Latin American (LATAM) countries due to differences in resources, expertise, and funding and local attitudes toward organ donation and transplantation. This current guidance of postoperative care after LT is the first position paper of the Latin American Association for the Study of the Liver (ALEH) Special Interest Group (SIG), drawing evidence-based recommendations regarding immediate and long-term postoperative care of LT recipients, taking into consideration their applicability in Latin America. © 2025 Fundación Clínica Médica Sur, A.C. Mención de responsabilidad : Codes, Liana; Zapata, Rodrigo; Mendizabal, Manuel; Junior, Alfeu de Medeiros Fleck; Restrepo, Juan Carlos; Schiavon, Leonardo de Lucca; Malbouisson, Luiz Marcelo Sá; Andraus, Wellington; Gadano, Adrian; Padilla-Machaca, P. Martin; Villamil, Alejandra; Stucchi, Raquel Silveira Bello; Castro-Narro, Graciela Elia; Pages, Josefina; Terrabuio, Debora Raquel Benedita; Urzúa, Alvaro; Pessoa, Mário Guimarães; Mainardi, Victoria; Pedro, Rodolpho; Imventarza, Oscar; Gerona, Solange; Wolff, Rodrigo; Abdala, Edson; Tenorio, Laura; Cerda-Reyes, Eira; Cairo, Fernando; Uribe, Mario; Bittencourt, Paulo Lisboa; Chong, Ricardo; Figueroa, Norma Marlene Perez; González, John Byron Abad; Murillo, Pablo Coste. Referencia : Ann Hepatol . 2025 Mar 7;30(2):101899. doi: 10.1016/j.aohep.2025.101899. DOI (Digital Object Identifier) : 10.1016/j.aohep.2025.101899 PMID : 40057036 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40057036/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002349 AC-2025-032 Archivo digital Producción Científica Artículos científicos Disponible
